Compugen Sells Controlling Stake In Keddem For $15M

Israeli pharmaceutical company Compugen, which develops genomics-based drug and diagnostic discovery tools, has sold its controlling stake in its subsidiary Keddem Bioscience. The acquisition, estimated to worth $15 million, was made by a privately owned US based investment company.